CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments
VANCOUVER, Washington, June 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Chief Operating Officer and Head of Clinical Development, will host an investment community webcast on Monday, June 21, 2021.
Management will provide a full discussion of the results from the recently unblinded data from its COVID-19 long-haulers trial, along with updates on COVID-19 trials in other countries, active trials for NASH and cancer, and regulatory advancements.
Management will provide approximately 60 minutes to address questions submitted online by analysts and investors.
|Date:||Monday, June 21, 2021|
|Time:||1:00 pm PT / 4:00 pm ET|
This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. Please note the below website will not be operational until approximately 60 minutes prior to the start of the webcast, which can be accessed via the following link:
The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until July 21, 2021.
Cristina De Leon
Released June 16, 2021